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Background:  Active calcification occurs within atherosclerotic plaque. Using positron emission (PET) and computed tomography (CT), we 
investigated coronary uptake of 18F-fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) in patients with stable angina and acute coronary 
syndrome (ACS).
methods:  We prospectively recruited 53 patients with either stable angina (n=29) or ACS (n=24). All patients underwent gated 18F-NaF and 
18F-FDG PET, and CT and invasive coronary angiography, with virtual histology intravascular ultrasound (VH-IVUS) in patients with stable angina 
(n=25).
results: In patients with stable angina, 11 (37%) had focal plaque 18F-NaF uptake (1.49 [1.25-1.99]) that, on VH-IVUS, had more necrotic core 
(25% vs 20%, p<0.05) and microcalcification (79% vs 22%, p<0.001) than plaques without 18F-NaF uptake. Intense 18F-NaF uptake occurred 
at the site of plaque rupture in patients with ACS (culprit lesion tissue-to-background ratio [TBR], 1.61 [1.50-1.75] vs maximum of all non-culprit 
plaques, 1.47 [1.25-1.50]; p<0.001; Fig 1). There were no differences in 18F-FDG uptake in culprit and non-culprit lesions (1.75 [1.36-2.22] vs 
1.56 [1.32-1.56] p=0.13) or between patients with stable angina and ACS (1.54 [1.25-1.89] vs 1.56 [1.32-1.56]; p=0.41).
conclusions:  18F-NaF holds major promise as a novel biomarker of coronary plaque vulnerability or rupture that has applications for risk 
stratification, development of novel therapeutic interventions and monitoring of disease progression.
 
